Overview

Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients

Status:
Completed
Trial end date:
2020-03-16
Target enrollment:
Participant gender:
Summary
The present trial is an exploratory study aiming at evaluating the safety, tolerability, and efficacy of a 15-day, once daily administration of 10 mg PBF-680 in subjects with persistent, mild-to-moderate atopic asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Palobiofarma SL
Collaborator:
Pivotal S.L.
Treatments:
Adenosine
Adenosine A1 Receptor Antagonists